title: Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer.
abstract: OBJECTIVE
  Approximately 20 to 40% of patients with surgically resected stage I non-small cell lung cancer (NSCLC) will develop recurrent disease. Positron emission tomography (PET) with 2-[18F] fluoro-2-deoxy-D-glucose (FDG) is used often in staging NSCLC. We conducted this study to determine whether the preoperative maximum tumor standardized uptake value (SUVmax) was associated with recurrence in patients with resected stage I NSCLC.
  
  
  METHODS
  We identified consecutive patients who underwent curative surgical resection for stage I NSCLC between 1999 and 2003 who had preoperative FDG-PET imaging. Patients were divided into two cohorts based on SUVmax above or below the median for the group. Recurrence rates were estimated by the Kaplan-Meier method and overall survival was analyzed as a secondary end point.
  
  
  RESULTS
  Of 136 patients who met inclusion criteria, 77 (57%) had T1 and 59 (43%) had T2 tumors. The median follow-up time was 46 months and 32 patients had a disease recurrence. The median SUVmax was 5.5. The 5-year estimates of recurrence rates for patients with low and high SUVmax were 14% and 37%, respectively (p = 0.002), with 5-year overall survivals of 74% and 53%, respectively (p = 0.006). In multivariate analyses based on SUVmax, T-classification, age, and histology, high SUVmax was independently associated with recurrence (p = 0.002) and mortality (p = 0.041).
  
  
  CONCLUSIONS
  High SUVmax (>or=5.5) on preoperative FDG-PET is an independent predictor of relapse and death in resected stage I NSCLC. Prospective trials of adjuvant chemotherapy in patients with stage I NSCLC and high SUVmax should be considered.
authors.affiliation: Division of Medical Oncology, Mallinckrodt Institute of Radiology.
authors.forename: Boone
authors.initials: B
authors.lastname: Goodgame
authors.forename: Giancarlo A
authors.initials: GA
authors.lastname: Pillot
authors.forename: Zhiyun
authors.initials: Z
authors.lastname: Yang
authors.forename: Jabi
authors.initials: J
authors.lastname: Shriki
authors.forename: Bryan F
authors.initials: BF
authors.lastname: Meyers
authors.forename: Jennifer
authors.initials: J
authors.lastname: Zoole
authors.forename: Feng
authors.initials: F
authors.lastname: Gao
authors.forename: Farrokh
authors.initials: F
authors.lastname: Dehdashti
authors.forename: Alexander
authors.initials: A
authors.lastname: Patterson
authors.forename: Barry A
authors.initials: BA
authors.lastname: Siegel
authors.forename: Ramaswamy
authors.initials: R
authors.lastname: Govindan
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000473:pathology / Q000601:surgery; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000601:surgery; D008297:Male; D015999:Multivariate Analysis; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D019275:Radiopharmaceuticals; D012008:Recurrence; D012307:Risk Factors
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18